Work Medical Technology Group Ltd. has announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II AI-Automated Human Blood Cell Morphology Analyzer. This regulatory approval marks a significant milestone for the company, enabling the production of a device that leverages advanced AI technology to improve the accuracy and efficiency of blood cell analysis. The analyzer, which is expected to be manufactured starting in the first half of 2026, aims to support early screening of blood disorders and reduce manual laboratory workloads.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Work Medical Technology Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617690-en) on December 29, 2025, and is solely responsible for the information contained therein.
Comments